Buy low, sell high is the mantra of the stock market. Turnstone Biologics Corp (NASDAQ: TSBX), a prominent player in the Biotechnology industry, is currently undervalued with a market value of
$3.36 compared to its real value of
$6.74. This discrepancy presents a potential opportunity for investors to maximize returns. The analyst overall consensus indicates a 'Buy' with two strong buys, one hold, and an estimated target price of $17, with the highest and lowest estimates being
$20 and $13 respectively. This suggests a significant potential for growth. However, it's important to remember that the stock market is unpredictable and it's crucial to conduct thorough research and consider the hype value of 3.5 before doubling your investment. In the current unique economic climate, Turnstone Biologics Corp may present investors with more surprises in the next two to three weeks. We will explore several reasons why the company still has the potential to generate above-average margins and positive cash flow. Currently, Turnstone Biologics Corp is trading at $3.36. The company has a historical hype elasticity of 0.14, while the average price elasticity to hype among its competitors is approximately 1.25.
The firm's value is projected to increase following the next major announcement, with the price expected to rise to $3.5. The current volatility of the media hype's impact on the company's stock price is significantly over 100 percent, making price predictions based on social media less reliable. The price increase following the next news release is projected to be 4.17%, while the daily expected return currently stands at -0.42%.
The volatility of related hype on Turnstone Biologics is about 530.28%, with the expected price after the next announcement by a competitor being $4.61. Given an investment horizon of 90 days, the next forecasted press release is expected to be released very soon.
The successful prediction of Turnstone Biologics
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Turnstone Biologics Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Turnstone Biologics based on Turnstone Biologics hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Turnstone Biologics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Turnstone Biologics's related companies.
Watch out for price decline
Please consider monitoring Turnstone Biologics on a daily basis if you are holding a position in it. Turnstone Biologics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Turnstone Biologics stock to be traded above the $1 level to remain listed. If Turnstone Biologics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Turnstone expected Price
Turnstone Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Turnstone Biologics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Turnstone Biologics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Turnstone Biologics Gross Profit
Turnstone Biologics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Turnstone Biologics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Turnstone Biologics Gross Profit growth over the last 10 years. Please check Turnstone Biologics'
gross profit and other
fundamental indicators for more details.
Breaking down Turnstone Biologics Further
This firm reported the previous year's revenue of 73.3
M. Net Loss for the year was (30.83
M) with profit before overhead, payroll, taxes, and interest of 71.13
M.
Deferred Revenue Breakdown
Turnstone Biologics Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2023. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. At this time, Turnstone Biologics' Deferred Revenue is fairly stable as compared to the past year.
| 2010 | 72.4 Million |
| 2022 | 19.31 Million |
| 2023 | 29.47 Million |
"As the saying goes, 'buy low, sell high,' and it seems that now may be the time to double down on your investment in Turnstone Biologics Corp (USA Stocks: TSBX). Despite a high probability of bankruptcy at 96.76%, the company's potential upside of 24.47 and a target price of $17 suggest a significant return on investment. With a market capitalization of
42.94M and gross profit of
71.13M, Turnstone Biologics Corp shows promise. However, investors should be aware of the company's high standard deviation of 15.59, indicating a high level of risk. The company's shares are primarily owned by institutions (34.17%), with insiders owning 8.79%. Despite the risks, the potential rewards may be worth the gamble for those willing to take on a high-risk, high-reward investment strategy."
Turnstone Biologics implied volatility may change after the rise
Turnstone Biologics Corp's stock has recently exhibited significant shifts in its implied volatility, as indicated by the coefficient of variation plunging to -4942.84. This substantial decrease suggests that the stock's volatility is becoming less unpredictable, potentially leading to more consistent trading patterns. However, investors should maintain vigilance as the implied volatility could alter following the recent surge in the stock's value. This could lead to unforeseen price swings, making it essential for investors to closely track Turnstone Biologics' performance in the upcoming weeks. Turnstone Biologics Corp is demonstrating above-average volatility over the chosen time frame. Investors should examine Turnstone Biologics Corp independently to ensure that their intended
market timing strategies align with their expectations about Turnstone Biologics' volatility. Understanding different
market volatility trends often assists investors in timing the market. Proper utilization of volatility indicators allows traders to gauge Turnstone Biologics' stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect
Turnstone Biologics' stock price while adding stress to investors as they witness their shares' value decline. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop.
The Bottom Line
While other entities in the biotechnology industry are either recovering or due for a correction, Turnstone may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Turnstone valuation and our trade advice on Turnstone Biologics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Turnstone Biologics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Nico Santiago is a PR Contributor to Macroaxis Editorial Board. Nico is a relatively new author here at Macroaxis and he likes to work on advertising and sponsored content and marketing for the company. Nico spends most of his time surfing when the weather is nice and he spends the rest of the year writing for various blogs and companies, as he works on his upcoming books, The Rise of the Financial Machines and Time Series Modelling with AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nico Santiago do not own shares of Turnstone Biologics Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]